Shingo Kasahara

Shingo Kasahara

Auto-generated profile, based on publicly available information

Shingo Kasahara

Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2010 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
SUShinya Ugaki
Shinya Ugaki
SKShingo Kasahara
Shingo Kasahara
YKYasuhiro Kotani
Yasuhiro Kotani
MNMahito Nakakura
Mahito Nakakura
TDTakuma Douguchi
Takuma Douguchi
SSShunji Sano
Shunji Sano

Verified
Journal Article
Open access
PDF file
YFYasuhiro Fujii
Yasuhiro Fujii
Tatsuyuki NakataniTatsuyuki Nakatani
Tatsuyuki Nakatani
Daiki OusakaDaiki Ousaka
Daiki Ousaka
SOSusumu Oozawa
Susumu Oozawa
YSYasushi Sasai
Yasushi Sasai
SKShingo Kasahara
Shingo Kasahara
The medical device market is a high-growth sector expected to sustain an annual growth rate of over 5%, even in developed countries. Daily, numerous patients have medical devices implanted or inserted within their bodies. While medical devices have significantly improved patient outcomes, as foreign objects, their wider use can lead to an increase in device-related infections, thereby imposing a burden on healthcare systems. Multiple materials with significant societal impact have evolved over time: the 19th century was the age of iron, the 20th century was dominated by silicon, and the 21st century is often referred to as the era of carbon. In particular, the development of nanocarbon materials and their potential applications in medicine are being explored, although the scope of these applications remains limited. Technological innovations in carbon materials are remarkable, and their application in medicine is expected to advance greatly. For example, diamond-like carbon (DLC) has garnered considerable attention for the development of antimicrobial surfaces. Both DLC itself and its derivatives have been reported to exhibit anti-microbial properties. This review discusses the current state of DLC-based antimicrobial surface development.

14 September 2021 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
DODaiki Ousaka
Daiki Ousaka
KHKenta Hirai
Kenta Hirai
NSNoriko Sakano
Noriko Sakano
MMMizuki Morita
Mizuki Morita
MHMadoka Haruna
Madoka Haruna
SKShingo Kasahara
Shingo Kasahara

19 November 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
KHKenta Hirai
Kenta Hirai
RSRyusuke Sawada
Ryusuke Sawada
THTomohiro Hayashi
Tomohiro Hayashi
TAToru Araki
Toru Araki
NNNaomi Nakagawa
Naomi Nakagawa
TGthe TICAP/PERSEUS Study Group
the TICAP/PERSEUS Study Group
Background: Cardiosphere‐derived cell (CDC) infusion was associated with better clinical outcomes at 2 years in patients with single ventricle heart disease. The current study investigates time‐to‐event outcomes at 8 years. Methods and Results: This cohort enrolled patients with single ventricles who underwent stage 2 or stage 3 palliation from January 2011 to January 2015 at 8 centers in Japan. The primary outcomes were time‐dependent CDC treatment effects on death and late complications during 8 years of follow‐up, assessed by restricted mean survival time. Among 93 patients enrolled (mean age, 2.3±1.3 years; 56% men), 40 received CDC infusion. Overall survival for CDC‐treated versus control patients did not differ at 8 years (hazard ratio [HR], 0.60 [95% CI, 0.21–1.77]; P =0.35). Treatment effect had nonproportional hazards for death favoring CDCs at 4 years (restricted mean survival time difference +0.33 years [95% CI, 0.01–0.66]; P =0.043). In patients with heart failure with reduced ejection fraction, CDC treatment effect on survival was greater over 8 years (restricted mean survival time difference +1.58 years [95% CI, 0.05–3.12]; P =0.043). Compared with control participants, CDC‐treated patients showed lower incidences of late failure (HR, 0.45 [95% CI, 0.21–0.93]; P =0.027) and adverse events (subdistribution HR, 0.50 [95% CI, 0.27–0.94]; P =0.036) at 8 years. Conclusions: By 8 years, CDC infusion was associated with lower hazards of late failure and adverse events in single ventricle heart disease. CDC treatment effect on survival was notable by 4 years and showed a durable clinical benefit in patients with heart failure with reduced ejection fraction over 8 years. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT01273857 and NCT01829750.

16 December 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
HOHideo Ohuchi
Hideo Ohuchi
KTKohta Takei
Kohta Takei
JMJun Muneuchi
Jun Muneuchi
SKShingo Kasahara
Shingo Kasahara
YIYuichi Ishikawa
Yuichi Ishikawa
MNMichikazu Nakai
Michikazu Nakai
Background: Management strategies of unplanned hospitalizations (UPH) vary and have not been well characterized in patients with Fontan circulation. Methods: We prospectively followed 3226 Fontan patients for 3 years to characterize the current UPH status and elucidate the associations between in‐hospital management strategies and postdischarge outcomes. Results: A total of 243 UPHs occurred (2.5 cases/100 person‐years). Fontan‐related UPHs accounted for 154 cases (63%), most commonly due to heart failure (19%), protein‐losing enteropathy (16%), hemorrhage (14%), arrhythmia (9%), thromboembolism (3%), and plastic bronchitis (2%). Fontan‐unrelated UPHs (89 cases; 37%) were mainly due to infections (19%). Adult patients were more frequently hospitalized for hemorrhage and thromboembolism ( P <0.05). The longest length of hospital stay was observed in protein‐losing enteropathy, followed by thromboembolism and heart failure. Among nonpharmacological treatments, oxygen therapy was commonly used, followed by surgical procedures and catheter‐based interventions. Among pharmacological treatments, diuretics were commonly administered, followed by heparin and catecholamines. Of 240 patients discharged alive, 76 (15.4 cases/100 person‐years) were readmitted. Protein‐losing enteropathy was the most frequent cause of readmission, followed by heart failure and hemorrhage. In addition to conventional risk factors, in‐hospital management practices, such as oxygen therapy, surgical intervention, and diuretic adjustment were associated with readmission risk ( P <0.01–0.001). Conclusions: We clarified real‐world practices related to UPHs in Fontan patients. Specific in‐hospital treatment strategies were associated with the risk of readmission. Further studies are warranted to determine the causal relationships between treatment approaches and outcomes for standardized management strategies.

7 April 2022 in Operative Techniques in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
SKShingo Kasahara
Shingo Kasahara
YKYasuhiro Kotani
Yasuhiro Kotani